FBRX stock forecast, quote, news & analysis
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications... Show more
FBRX's Stochastic Oscillator is sitting in overbought zone for 15 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 14, 2026. You may want to consider a long position or call options on FBRX as a result. In 68 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
Following a +0.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where FBRX advanced for three days, in 179 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Advertisement
General Information
a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer
Industry Biotechnology